Jennifer Brown is an Oncology physician. ClinicalTrials.gov lists 14 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
18980 W Memorial Dr Ste 440
Humble, TX 773384559
Telephone
832-616-5190Provider last certified this registry record 7 Nov 2022.
Clinical trials
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Sponsor: Alliance for Clinical Trials in Oncology
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Aroa Biosurgery IncorporatedProgram year20252 payments
- Tempus AI, IncProgram year20257 payments
- ABBVIE INC.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56%Other antiemetics52.7%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist3.2%Palonosetron hcl95%Ondansetron Hcl3%Ondansetron Odt2%Part D + Part B<11 patientsBlood & clotting
36.5%Parenteral Iron Replacement36.4%Iron sucrose100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.1%Eliquis100%Part D<11 patientsSensory organs
5%Corticosteroid5%Dexamethasone sodium phosphate91%Dexamethasone7%Clobetasol Propionate2%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2014–2023 per NIH RePORTER. The latest:
- Cultural Consensus Modeling to Identify Culturally Relevant Risk Factors for Suicide among Black Youth
University of Houston
FY2023$204,488R21MH128570 - Cultural Consensus Modeling to Identify Culturally Relevant Risk Factors for Suicide among Black Youth
University of Houston
FY2022$265,259R21MH128570 - Impact of Drug Use Treatment on HIV Risk Behaviors: An Integrative Data Analysis
Texas Tech University
FY2015$6,138R03DA037786
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”